These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20211715)

  • 1. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
    Jones MD; Santo JG; Yakub B; Dennison M; Master H; Buckton G
    Int J Pharm; 2010 May; 391(1-2):137-47. PubMed ID: 20211715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of carrier surface fines on dry powder inhalation formulations.
    Boshhiha AM; Urbanetz NA
    Drug Dev Ind Pharm; 2009 Aug; 35(8):904-16. PubMed ID: 19466888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of high shear mixing on ternary dry powder inhaler formulations.
    Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
    Int J Pharm; 2017 Dec; 534(1-2):242-250. PubMed ID: 29051120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.
    Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
    Int J Pharm; 2018 Jan; 535(1-2):59-67. PubMed ID: 29100914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers.
    Young PM; Wood O; Ooi J; Traini D
    Int J Pharm; 2011 Sep; 416(1):129-35. PubMed ID: 21708238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS; Lau R
    Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
    Sun Y; Qin L; Li J; Su J; Song R; Zhang X; Guan J; Mao S
    AAPS J; 2021 Apr; 23(3):55. PubMed ID: 33856568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance.
    Shah SP; Misra A
    Pharmazie; 2004 Oct; 59(10):812-3. PubMed ID: 15544064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of carrier particle shape on dry powder inhaler performance.
    Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
    Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H; Markefka P; teWierik H; Kammelar R
    Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances.
    Jones MD; Harris H; Hooton JC; Shur J; King GS; Mathoulin CA; Nichol K; Smith TL; Dawson ML; Ferrie AR; Price R
    Eur J Pharm Biopharm; 2008 Jun; 69(2):496-507. PubMed ID: 18191553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrostatic characterisation of inhaled powders: effect of contact surface and relative humidity.
    Elajnaf A; Carter P; Rowley G
    Eur J Pharm Sci; 2006 Dec; 29(5):375-84. PubMed ID: 16952450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance.
    Cordts E; Steckel H
    Eur J Pharm Biopharm; 2012 Oct; 82(2):417-23. PubMed ID: 22902789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.